In a major step toward treating rare neurological diseases, scientists have used gene editing to correct mutations inside the brain of living mice with a single injection. This new approach, described ...

Our understanding of DNA has grown dramatically over the past couple of decades. The CRISPR technology, which allows scientists to map and even change DNA, has helped to boost that understanding even ...

Scientists have corrected gene mutations in mice causing an ultra-rare disease by editing DNA directly in the brain with a single injection, a feat with profound implications for patients with ...

Complexities like these make it challenging to develop broadly applicable gene therapies for these disorders. Researchers at The University of Texas at Austin now have developed an improved method of ...

A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...

DENVER, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CRISPR gene-editing, and related genome engineering technologies, are reshaping industries from medicine to materials, with breakthroughs in treating genetic ...

Gene-editing techniques such as CRISPR-Cas9 have many uses in the area of food and agriculture. They can combat persistent drought and disease, and improve the colour and nutritional content of food ...

Epigenome editing has followed a similar path, in that more recent technological breakthroughs have enabled scientists to apply the discoveries made in previous decades. Epigenome editing performs a ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

It's been seven years since Chinese biophysicist He Jiankui made an announcement that shocked the world's scientists. He had made the world's first gene-edited babies. Through rewriting DNA in twin ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...